Overview of Fentanilo Labesfal

This section provides an overview of the identity, composition, and high-level classification of Fentanilo Labesfal.

Property	Description
Active ingredient	Fentanyl (often as Fentanyl citrate)
Form	Solution for injection, Transdermal patch, Transmucosal preparations
Pharmacological class	Opioid analgesic / Narcotic analgesic
Common use	Strong pain relief (profound analgesia)
Origin	Synthetic opioid derivative

What Type of Medicine is Fentanilo Labesfal?

Fentanilo Labesfal is a pharmaceutical preparation containing the active ingredient Fentanyl, which is formally classified as a synthetic opioid analgesic. This compound is a powerful narcotic analgesic and a derivative of piperidine, confirming its entirely synthetic origin rather than being naturally derived from opium. The substance is clinically recognized for its high affinity for the mu-opioid receptor (MOR), which defines its class. Pharmacological studies confirm Fentanyl is a potent short-acting analgesic with a high therapeutic index. The drug helps ease severe pain by acting directly on the central nervous system to block pain signals.

Fentanyl: Potency and Primary Purpose

The primary purpose of Fentanyl is to provide profound analgesia, meaning exceptionally strong pain relief, which is achieved by its selective action as a mu-opioid receptor (MOR) agonist. Fentanyl is substantially more potent than many other standard opioids, demonstrating high intrinsic efficacy at these receptors. This high potency means the drug can provide robust pain management even at very low concentrations, making it essential for situations that demand highly effective pain control, such as in anesthesia or post-operative care. Its therapeutic role is strictly limited to the management of severe, intense pain states that require immediate and strong pharmacological intervention.

Composition and General Forms of Fentanyl

The active substance is typically utilized as the salt Fentanyl citrate in pharmaceutical preparations. Fentanilo Labesfal specifically references formulations often in the form of a sterile solution for injection (parenteral administration), which facilitates immediate action. However, the Fentanyl entity is also associated with a wide array of other dosage form(s) for the same active ingredient, including transdermal patch systems designed for prolonged, continuous release, and various transmucosal preparations. Each final preparation consists of Fentanyl as a single active ingredient product, incorporated into its corresponding base or vehicle.

What side effects are possible with Fentanilo Labesfal?

Possible Side Effects and Safety Information

The safety profile for Fentanyl, the active ingredient in Fentanilo Labesfal, is officially classified by regulatory agencies based on the frequency of occurrence and the affected physiological system, primarily focusing on Central Nervous System (CNS), Gastrointestinal (GI), and Cardiopulmonary effects.

Frequency-Based Adverse Reactions

Adverse reactions are grouped by official frequency tiers:

Very Common (ge 1/10): Nausea and Vomiting.
Common (ge 1/100 to < 1/10): Dizziness, Somnolence (Drowsiness), Headache, Sweating, Pruritus (Itching), Constipation, Dry Mouth, Confusion, Anxiety, and changes in blood pressure (Hypotension/Hypertension).
Uncommon (ge 1/1,000 to < 1/100): Arrhythmia (Irregular heartbeat) and Apnea (Temporary cessation of breathing).

Serious Adverse Reactions and Safety Constraints

The most serious risk documented in regulatory labels is life-threatening respiratory depression. Other serious adverse reactions include the risks of developing Tolerance and Opioid Use Disorder (Dependence), which are associated with long-term exposure. Safety constraints explicitly define that this medicine is contraindicated for use in individuals who are not opioid tolerant, or those with severe pre-existing conditions such as severe respiratory depression.

Population-Specific Safety Notes

Official documents note that older adults may be more susceptible to adverse effects, including respiratory depression. Patients with renal or hepatic impairment may also experience a higher risk of adverse effects due to altered drug clearance, requiring specific consideration in the overall safety assessment. Furthermore, prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome in the newborn.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile defines Fentanilo Labesfal (Fentanyl) overdose as a serious medical emergency rooted in the extension of its pharmacological actions. The primary life-threatening manifestation is severe respiratory depression, which can rapidly progress to respiratory failure, coma, and death. Documented clinical signs include profound sedation, stupor, pinpoint pupils (miosis), cyanosis (bluish skin discoloration), and cold, clammy skin.

Immediate medical help must be sought upon any suspicion of overdose; official guidance mandates calling emergency services immediately. Management is primarily symptomatic and supportive. Required emergency measures involve establishing and maintaining a patent airway, providing assisted or controlled ventilation with oxygen, and administering an opioid antagonist (e.g., naloxone) to reverse the effects. Regulatory information notes that repeated antagonist doses may be necessary, and hospital monitoring is required to ensure sustained respiratory recovery.

Population-specific notes highlight increased toxicity risk in elderly patients and those with hepatic or renal impairment. Accidental exposure or ingestion, particularly in children, poses a critical risk of fatal outcome.

Therapeutic Uses of Fentanilo Labesfal

Fentanilo Labesfal is commonly used across domains where additional symptomatic support is needed in situations involving certain distressing symptoms.

Supportive Relief in Acute Symptom Manifestations

This medication is commonly used to help manage symptoms related to physical discomfort during surgical procedures, in critical care, or immediately following trauma or surgery. It is generally applied in scenarios where additional management of discomfort is required in clinical settings. The medicine provides supportive relief that contributes to easing the overall symptom load in conditions marked by increased physiological stress.

Managing Breakthrough and Recurrent Discomfort

Fentanilo Labesfal is considered relevant across conditions characterized by periods of heightened symptoms in patients who are already receiving long-term treatment for persistent discomfort. It is relevant for managing symptoms that interfere with daily comfort, particularly symptoms that become more disruptive during flare-ups—known as breakthrough pain—that can occur unpredictably. By offering appropriate short-term symptomatic assistance, the medication supports patients during episodes of heightened discomfort and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relevant for Symptoms Related to Physical Discomfort in Acute and Chronic Contexts.

Eligibility and Restrictions for Use

Fentanilo Labesfal, like all potent opioids, has strict eligibility criteria and is contraindicated in several patient populations due to the risk of severe side effects, especially life-threatening respiratory depression.

Populations for Whom Use is Restricted or Prohibited

Contraindicated:

Patients with a documented hypersensitivity or intolerance to fentanyl, other opioids, or any component of the formulation.
Patients with severe respiratory disease, severe obstructive lung conditions, or bronchial asthma.
Patients who have received a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.
Children under two years of age (safety and efficacy are not established).

Special Caution/Dose Reduction Required:

Elderly or debilitated patients are more susceptible to adverse effects and require an initial dose reduction and careful titration.
Patients with impaired hepatic (liver) or renal (kidney) function must be monitored closely for signs of toxicity.
Patients with head injuries or conditions causing increased intracranial pressure.
Pregnant women (regular use may cause neonatal opioid withdrawal syndrome) and nursing women (fentanyl is secreted in breast milk; use is generally not recommended).
Patients with pre-existing conditions like uncontrolled hypothyroidism or cardiac bradyarrhythmias.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fentanilo Labesfal can have clinically significant interactions with several classes of medicinal products, primarily due to effects on the central nervous system (CNS) and its metabolic pathway.

Interacting Product Category	Potential Effect	Interaction Management
CNS Depressants (e.g., Benzodiazepines, Alcohol, other Opioids, Sedatives, General Anesthetics)	Additive or synergistic CNS depression, leading to profound sedation, respiratory depression, coma, and death.	Reserve concurrent use for when alternative options are inadequate. Limit dosage and duration, and monitor closely.
CYP3A4 Inhibitors (e.g., Macrolide Antibiotics, Azole Antifungals, HIV Protease Inhibitors)	Increase in Fentanyl plasma concentration, which can prolong or increase both therapeutic effects and potentially fatal respiratory depression.	Requires close monitoring; a dosage reduction of Fentanyl may be necessary.
Serotonergic Drugs (e.g., SSRIs, SNRIs, MAOIs)	Risk of Serotonin Syndrome, a potentially life-threatening condition. Monoamine Oxidase Inhibitors (MAOIs) are generally contraindicated or strongly discouraged.	Monitor for symptoms; discontinue Fentanyl if Serotonin Syndrome is suspected.
CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, Phenytoin)	Decrease in Fentanyl plasma concentration, risking reduced analgesic efficacy or precipitation of withdrawal symptoms.	Monitor for reduced effectiveness, particularly after an inducer is stopped.
Mixed Agonist/Antagonist Opioids (e.g., Butorphanol, Pentazocine)	May reduce the analgesic effect of Fentanyl or precipitate withdrawal symptoms.	Avoid concomitant use.

Mechanism of Action

Fentanilo Labesfal functions as a synthetic opioid agonist, primarily targeting the mu-opioid receptor (muOR), a G protein-coupled receptor (GPCR), predominantly located throughout the central and peripheral nervous systems. Upon binding to the muOR, the compound induces a conformational change that enables receptor coupling with inhibitory Gi/Go proteins.

This interaction initiates an intracellular signaling cascade, specifically by promoting the exchange of GTP for GDP on the alpha-subunit of the G protein. Activation of the Gi/Go pathway leads to the inhibition of the enzyme adenylate cyclase, resulting in a decrease in the intracellular concentration of cyclic adenosine monophosphate (cAMP). Simultaneously, G protein activation facilitates the opening of G protein-coupled inwardly-rectifying potassium channels (GIRK) and inhibits voltage-gated calcium channels.

The net intracellular consequences are cellular hyperpolarization due to enhanced potassium efflux and a reduction in neurotransmitter release from the presynaptic terminal due to decreased calcium influx. System-level physiological modulation occurs through the resulting inhibition of neuronal excitability and signal transmission within the central nervous system.

Dosage and Administration Information

How Fentanilo Labesfal is Used: Official Administration Guidelines

Fentanilo Labesfal (Fentanyl Solution for Injection) is a prescription medicine used in accordance with established clinical standards to ensure proper administration in a supervised setting. All instructions are based on official prescribing information.

Official Routes and Setting

This medication is primarily administered via Intravenous (IV) injection (bolus or infusion) or Intramuscular (IM) injection. Administration must only occur in environments where the patient’s airway can be secured and managed, such as a hospital or operating room, and only by trained professionals.

Standard Dosing and Frequency

Dosages are highly individualized and determined by the supervising clinician based on the patient's condition and the medical procedure.

Regimen Context	Typical Dosing Principles
Low-Dose Analgesia	Initial IV doses range from 50 mu g to 200 mu g (micrograms).
Supplemental Doses	50 mu g to 200 mu g administered as needed, typically every 30 to 45 minutes for IV maintenance.
Post-Operative	50 mu g to 100 mu g IM, repeatable after one or two hours, as necessary.

Preparation and Procedural Rules

For continuous administration, Fentanyl solution may be diluted prior to use. It is chemically incompatible with certain alkaline solutions, which should not be mixed with the product. When administered as an IV bolus, the injection must be given slowly.

Population-Specific Use Adjustments

Dose adjustments are required for certain patient groups. The initial dose for older adults and those with hepatic or renal impairment must be reduced. For obese patients, the dosage should be based on their estimated lean body mass rather than total body weight.

Recent Clinical Evidence

Fentanilo Labesfal: Overview of Research

Research has explored the use of fentanyl in managing severe pain, particularly in settings where rapid action is necessary, such as breakthrough cancer pain and acute postoperative pain. Studies primarily focus on characterizing its effects and comparing outcomes with other opioid analgesics.

Key Trial Findings

Randomized controlled trials (RCTs) have compared fentanyl to other opioids, primarily morphine, in various acute pain settings. For severe postoperative pain, one RCT found that equipotent doses of intravenous fentanyl and morphine were associated with similar effectiveness in reducing pain to mild-to-moderate levels after the initiation of rescue analgesia, without significant differences in adverse events like respiratory depression or nausea.

Fentanyl's high lipid solubility, which allows for rapid passage across the blood-brain barrier, is a key focus of pharmacokinetic studies, supporting its utility when quick analgesic onset is desired, such as for the treatment of breakthrough cancer pain (BTcP). Different transmucosal formulations of fentanyl have been studied specifically for BTcP, with research indicating that these rapid-onset opioids may correlate with significant pain relief compared to placebo in opioid-tolerant patients.

Safety and Tolerability Data

Long-term observational data and systematic reviews have assessed safety and tolerability. Research on transdermal fentanyl for chronic non-cancer pain, while limited, suggested a lower incidence of constipation compared to oral sustained-release morphine. However, the use of all potent opioids requires careful monitoring due to known risks, including respiratory depression and the development of tolerance and dependence. Studies consistently emphasize that treatment populations generally include individuals who are already opioid-tolerant or have specific clinical needs, such as cancer pain.

Frequently Asked Questions (FAQ)

Common questions about Fentanilo Labesfal (FAQ)

Q: What is the classification of Fentanilo Labesfal in terms of controlled substances?

The active ingredient, Fentanyl, is classified in the United States as a Schedule II controlled substance by the Drug Enforcement Administration (DEA). This classification is used for substances that regulatory bodies recognize as having a high potential for abuse and dependence.

Q: Does Fentanilo Labesfal carry a boxed warning from the FDA or equivalent agency?

Yes, Fentanyl injection products carry a serious Boxed Warning issued by the FDA. This warning highlights the risks associated with the medication, including addiction, abuse, misuse, and life-threatening respiratory depression. The warning also highlights the serious risk associated with using it alongside other Central Nervous System (CNS) depressants.

Q: What is the difference between Fentanilo Labesfal and other pain management treatments?

Fentanyl is a potent synthetic opioid analgesic described by regulatory bodies as substantially more potent than many standard opioids, such as morphine. It is designed to manage severe pain that requires immediate and highly effective pharmacological intervention, such as during anesthesia or post-operative care.

Q: How is Fentanilo Labesfal different from immediate-release fentanyl?

Fentanilo Labesfal, as a solution for injection, is used to provide immediate, short-duration pain relief, often in acute clinical settings. Immediate-release fentanyl forms are often highly specialized for treating 'breakthrough' pain in patients who are already opioid-tolerant.

Q: Is Fentanilo Labesfal intended for continuous, around-the-clock use?

The solution for injection is primarily intended for use in acute settings like surgery or the immediate post-operative period. Continuous, around-the-clock pain management is typically handled by other formulations of Fentanyl, such as the transdermal patch systems.

Q: How long does it usually take to feel the described effects of Fentanilo Labesfal?

When Fentanyl is administered intravenously in a clinical setting, it is known to have a very rapid onset of effect. Official pharmacological data indicates that the pain-relieving effects typically begin within minutes or less of administration.

Q: What is the typical duration of action for Fentanilo Labesfal?

Fentanyl is classified as a short-acting opioid analgesic. After a single injection, the duration of its analgesic effect is generally brief, usually 30 to 60 minutes.

Q: Is it possible for the effects of Fentanilo Labesfal to wear off suddenly?

Fentanyl is a short-acting drug, meaning the analgesic effect is brief, often lasting less than an hour. However, the respiratory depressant effect may persist longer than the pain relief. This is why the administration and monitoring of the medication occur in a supervised clinical setting.

Q: Does Fentanilo Labesfal have a potential for misuse or diversion?

Yes. Official warnings explicitly state that Fentanyl exposes users to risks of addiction, abuse, and misuse. These serious risks can potentially lead to overdose and death, and its controlled substance classification reflects this potential.

Q: Is Fentanilo Labesfal known to cause withdrawal symptoms if stopped suddenly?

Official regulatory information warns that stopping opioid medicines suddenly, including fentanyl, in patients who are physically dependent can lead to serious withdrawal symptoms. For this reason, administration and discontinuation are typically managed under professional supervision.

Q: Can Fentanilo Labesfal impact a patient's sleep patterns?

Yes, official adverse reaction listings include effects that can impact sleep. Both somnolence (drowsiness) and insomnia (difficulty sleeping) are cited as possible effects in the official product information.

Q: Are muscle spasms or twitching described as a side effect of Fentanilo Labesfal?

Official documents for Fentanyl injection note the risk of involuntary muscle movement, specifically known as skeletal muscle rigidity. This effect is more commonly observed when the medication is administered very rapidly into a vein.

Q: How often are serious skin reactions described with Fentanilo Labesfal?

Official regulatory labeling lists adverse reactions by frequency, including possible hypersensitivity reactions. While serious skin reactions are generally rare, they are associated with a hypersensitivity risk, which is a known caution for all medications.

Q: Does Fentanilo Labesfal have a warning regarding mental health changes?

Yes. The official adverse reaction listings include changes in mental state. Common side effects described in regulatory documents include confusion and anxiety.

Q: Does the official labeling mention any lifestyle changes needed while using Fentanilo Labesfal?

Yes. Due to the risk of profound sedation and dizziness, official labeling advises against certain activities. Patients should not drive or operate dangerous machinery while under the influence of this medication.

Q: Does grapefruit juice interact with Fentanilo Labesfal?

Yes, official drug interactions guidance warns that consuming grapefruit or grapefruit juice should be avoided while using Fentanyl. Regulatory warnings indicate that these products may increase the blood levels of the medication, which can elevate the potential for serious adverse effects, including respiratory depression.

Q: Can Fentanilo Labesfal be used simultaneously with anti-depressants?

Caution is required, as Fentanyl can interact with certain antidepressants known as serotonergic drugs. This interaction can lead to a potentially life-threatening condition called Serotonin Syndrome, which requires careful monitoring.

Q: Does Fentanilo Labesfal interact with common over-the-counter pain relievers?

Common non-opioid pain relievers like Acetaminophen or Ibuprofen are not typically listed as major interacting agents in the regulatory documents for Fentanyl. However, official information stresses caution with all Central Nervous System (CNS) depressant drugs, which can include some common over-the-counter cold and cough remedies.

Q: Is Fentanilo Labesfal generally appropriate for adolescents?

Official guidance generally states that use in children under two years of age is contraindicated. For adolescents, official guidance states that appropriateness of use is determined by a healthcare provider based on the specific clinical indication and the patient’s opioid tolerance status.

Q: What does official guidance say about using Fentanilo Labesfal during pregnancy planning?

Regular use of Fentanyl during pregnancy is documented to potentially harm the fetus and can result in Neonatal Opioid Withdrawal Syndrome in the newborn. Regulatory guidance states that the need for this medication during pregnancy or planning must be assessed by a physician.

Q: Has Fentanilo Labesfal been studied in populations with chronic, non-cancer pain?

Fentanyl products are generally not indicated for or are contraindicated for use in the management of acute or chronic non-cancer pain. Their therapeutic role is limited to highly specific and severe pain situations where other options are inadequate.

Q: What research has been published on the long-term efficacy of Fentanilo Labesfal?

Clinical trials for Fentanyl injection focus on acute pain settings, where rapid, short-term efficacy is the primary goal. Long-term efficacy data is more commonly associated with chronic-use formulations, like the transdermal patch, which are designed for continuous treatment.

Q: What official resources are available to learn more about Fentanilo Labesfal?

Official information can be obtained directly from governmental drug regulatory agencies, such as the FDA or EMA. Patient-focused government resources, like the NIH's MedlinePlus Drug Information, are also available for learning more about Fentanyl.

How should Fentanilo Labesfal be stored and disposed of?

How to Store and Dispose of Fentanilo Labesfal

Fentanilo Labesfal must be stored and handled according to regulatory requirements to maintain its stability and ensure security.

Storage Requirements

Condition	Requirement
Temperature	Store below 25 C (77 F); do not freeze.
Protection	Keep in the outer carton and original container for protection from light.
Child-Safety	Must be kept safely out of the sight and reach of children.

Stability and Disposal

When diluted, the physicochemical stability of the solution is demonstrated for 24 hours at 25 C, though immediate use is recommended microbiologically. Disposal of unused or expired product must be carried out according to local requirements for narcotic medicinal products. The medicine must not be flushed down a toilet or poured down a sink, and should be disposed of via a drug take-back program or an officially recommended secure method.

Fentanilo Labesfal